|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In conjunction with prior evidence linking EPO mRNA expression levels and tumor size, E<sub>2</sub>-stimulated EPO mRNA expression may explain the marked growth disparities seen in these tumors.
|
30554729 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This phenomenon could explain the development of early onset of polycythemia in the absence of erythropoietin-secreting tumors.
|
30644531 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Although erythropoietin-producing human hepatocellular receptor A2 (EphA2) signaling serves an important role in the tumor microenvironment, its contribution to vasculogenic mimicry (VM) formation in gastric cancer cells remains unclear.
|
31452781 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The incorporation of TAM into NLC with and without EPO coat had significantly (p<0.05) improved specificity and safety of the drug carriers in the treatment of mammary gland tumors.
|
31291309 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Because recent studies have demonstrated that EPO and its receptor (EPOR) are expressed in several tumors and can promote tumor growth, in the present study, we investigated EPO and EPOR expression in human glioma and the effect of EPO administration in a rat model of glioma implantation.
|
31658577 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Binocrit<sup>®</sup> (HX575) is a biosimilar version of epoetin alfa, indicated in the oncology setting for the treatment of chemotherapy-induced anemia (CIA).
|
29707043 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The question has been raised whether Epo promotes tumor growth and inhibits the death of cancer cells.
|
29345289 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Among those are elevated serum erythropoietin (EPO) levels caused by secretion of the tumor or associated tumor cyst.
|
30214643 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recombinant human EPO is currently used clinically for the treatment of anemia in patients with end-stage renal disease, and in certain cancer patients suffering from anemia induced either by the tumor itself or by chemotherapy.
|
28871174 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Numerous tumor cells express the EPO receptor (EPOR), posing a risk that EPO treatment would enhance tumor growth, but the mechanisms involved in breast tumor progression are poorly understood.Here, we have examined the functional role of the EPO-EPOR axis in pre-clinical models of breast cancer.
|
28418910 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Erythropoietin (EPO) is the main regulator of erythropoiesis, and its receptor (EPOR) is expressed in various tissues, including tumors.
|
28714517 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, PADI2 might have deleterious effects on tumor growth and metastasis in liver tumor cells by regulating the expression of EPO, a gene with controversial functions in tumor growth.
|
28331341 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
With primary tumor cell culture and patient-derived tumor xenograft (PDX) mouse model, the EPO secretion from the tumors of these 14 patients was verified.
|
29137269 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Employing an in vivo model of B16 murine melanoma, we observed that administration of EPO to tumor bearing C57BL/6 mice resulted in pronounced acceleration of melanoma growth.
|
28415825 |
2017 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Gain-of-function studies show that EPO protects tumor vessels from anti-VEGF treatment and compromises its antitumor effects.
|
29078273 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We assessed the EPO expression in leiomyomas and investigated the effects of EPO on the tumor growth.
|
25724399 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Erythropoietin Stimulates Tumor Growth via EphB4.
|
26481148 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In the in vivo study in the subcutaneous and intracranial glioblastoma models, the tumor size was reduced more effectively in the pEpo-NI2-SV-HSVtk group than in the control and pSV-HSVtk groups.
|
24467192 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We have previously shown that erythropoietin in combination with surgical trauma stimulates tumour growth.
|
25182342 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Additional concerns arise in cancer patients due to the ability of erythropoietin to act as an angiogenic and, in general, as a cell growth factor, because this might favour the progression of neoplastic disease.
|
24059228 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Darbepoetin (DPO), an erythropoietin (EPO) derivative, was licensed in 2002 to treat patients with solid tumors suffering from chemotherapy-dependent anemia, although various tumors express EPO to improve vascularization, thus favoring tumor growth and spreading.
|
23877120 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Vaccinia virus-mediated expression of human erythropoietin in tumors enhances virotherapy and alleviates cancer-related anemia in mice.
|
23765443 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Surgical removal of the tumors only temporarily normalized plasma erythropoietin (Epo) levels and discontinued phlebotomies.
|
23539726 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In the present work we analyzed the gene expression of EPO and its cognate receptor (EpoR) in a rat model of thioacetamide-induced damage and tumor.
|
23052842 |
2013 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Erythropoietin-driven proliferation of cells with mutations in the tumor suppressor gene TSC2.
|
21036916 |
2011 |